Cargando…
Hemodynamic effects of fluoxetine in pulmonary arterial hypertension: an open label pilot study
In order to evaluate the therapeutic potential of fluoxetine in pulmonary arterial hypertension, 13 patients with pulmonary arterial hypertension underwent catheterization before and after 12 (N = 5) or 24 (N = 8) weeks fluoxetine therapy. No change was seen in the primary endpoint of pulmonary vasc...
Autores principales: | Sodimu, Adetoun, Bartolome, Sonja, Igenoza, Oluwatosin P., Chin, Kelly M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691907/ https://www.ncbi.nlm.nih.gov/pubmed/33282204 http://dx.doi.org/10.1177/2045894020971954 |
Ejemplares similares
-
Prognosis of pulmonary arterial hypertension patients with pericardial effusion before and after initiation of parenteral prostacyclin therapy
por: Abu‐Rmaileh, Muhammad, et al.
Publicado: (2023) -
Transitioning Stable Patients with Pulmonary Arterial Hypertension from Parenteral Prostanoids to Oral Selexipag
por: Hinkamp, Colin, et al.
Publicado: (2022) -
An Open-label Trial of Risperidone and Fluoxetine in Children with Autistic Disorder
por: Desousa, Avinash
Publicado: (2010) -
Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension
por: Humbert, Marc, et al.
Publicado: (2023) -
Vorticity for the assessment of pulmonary vascular hemodynamics in pulmonary arterial hypertension
por: Honeyman, Alexander, et al.
Publicado: (2014)